DermRx Decision Support
Dermatology

Evidence-based
drug selection
for dermatology

Start from a drug class or from a diagnosis. Either route narrows the options by patient profile and comorbidities, with contraindication alerts.

Start with a drug class
💉
Injection-based therapies
Biologics &
Immunotherapies
Licensed biologics across psoriasis, generalized pustular psoriasis, atopic dermatitis, HS, prurigo nodularis, CSU, bullous pemphigoid and pemphigus vulgaris, plus the checkpoint inhibitors and oncolytic viral therapies approved for melanoma.
IL-17 inhibitors IL-23 inhibitors TNF-α inhibitors IL-4Rα inhibitors IL-13 inhibitors IL-31Rα Anti-IgE Anti-CD20 Checkpoint inhibitors Oncolytic viral therapy
Open biologics form →
💊
Oral & topical therapies
JAK & TYK2
Inhibitors
Oral and topical small molecule inhibitors for psoriasis, atopic dermatitis, alopecia areata, vitiligo, chronic hand eczema and dermatomyositis. Includes black box warning screening.
Upadacitinib Abrocitinib Baricitinib Deucravacitinib Ruxolitinib cream Ritlecitinib Brepocitinib
Open JAK/TYK2 form →
or
Start with a diagnosis
Plaque Psoriasis
Atopic Dermatitis
Hidradenitis Suppurativa
Alopecia Areata
Chronic Spontaneous Urticaria
Prurigo Nodularis
Melanoma
Basal Cell Carcinoma
Cutaneous Squamous Cell Carcinoma
Merkel Cell Carcinoma
Cutaneous T-Cell Lymphoma
→

Not a substitute for clinical judgment or institutional prescribing guidelines. For educational and clinical decision support purposes only.

Pipeline & ongoing clinical trials Updated October 14, 2026
Superficial Basal Cell Carcinoma
FDA Approved
Topical photosensitizer (ALA prodrug). FDA approved September 14, 2026 (sNDA) for superficial basal cell carcinoma (sBCC) in adults (≥18y) in combination with photodynamic therapy via BF-RhodoLED® lamp. First and only topical PDT drug FDA-approved to treat a skin cancer. Ameluz was previously marketed for actinic keratosis (AK). Mechanism: ALA is converted intracellularly to protoporphyrin IX; red-light activation generates reactive oxygen species that selectively destroy tumor cells. HCP-administered only. Key warnings: photosensitivity (avoid sunlight/bright indoor light to treated areas after application until illumination is complete); use only with approved BF-RhodoLED® or RhodoLED® XL lamp. No BBW. Phase 3 trial NCT03573401 supported approval. Commercial rollout for sBCC indication planned late Q4 2026 – Q1 2027.
Melanoma
FDA Approved
Genetically modified oncolytic viral therapy (HSV-1-based; encodes GALV-GP-R− fusogenic glycoprotein + GM-CSF; ICP34.5 and ICP47 deleted). FDA granted accelerated approval August 6, 2026 for unresectable advanced cutaneous melanoma in combination with nivolumab in adults (≥18y) who experienced disease progression on a PD-1–blocking antibody-based regimen. Administered by intralesional injection. First oncolytic viral therapy approved in the US since T-VEC (Imlygic) in 2015. Breakthrough Therapy and Priority Review designations. Efficacy: ORR 24.2% (95% CI 15.8–34.3); median DOR 14.1 months (IGNYTE trial, n=91 efficacy-evaluable). Confirmatory trial IGNYTE-3 ongoing. No BBW.
Plaque Psoriasis
FDA Approved
IL-23 inhibitor. Approved June 26, 2026 for moderate-to-severe plaque psoriasis and active psoriatic arthritis in patients ≥6y. Weight-based dosing: 55mg SC (<40kg) or 150mg SC (≥40kg) at wk0, wk4, then q12wks. New 55mg prefilled syringe simultaneously approved. PsA approval extrapolated from psoriasis data (OptIMMize-1/2 trials). Previously approved for adults only.
FDA Approved
Topical PDE4 inhibitor. Approved June 29, 2026 for plaque psoriasis (including intertriginous areas) in patients ≥2y. Once daily; no duration restriction. First topical PDE4 inhibitor approved for psoriasis in patients under 6. Contraindicated in moderate-to-severe hepatic impairment (Child-Pugh B or C). Supported by MUSE pediatric PK/safety study.
FDA Approved
First oral IL-23R antagonist (cyclic peptide). Approved March 18, 2026 for plaque psoriasis ≥12y and ≥40kg. 200mg once daily oral. Superior to deucravacitinib in head-to-head Phase 3 (PASI 90: 55% vs 30%). No BBW. ICONIC-ASCEND (vs. ustekinumab) ongoing.
FDA Approved
IL-23 inhibitor (p19 subunit). FDA approved October 30, 2026 (sBLA) for active psoriatic arthritis (PsA) in adults (≥18y), expanding beyond the prior plaque psoriasis-only indication. Dosing: 100 mg SC at Weeks 0 and 4, then every 12 weeks; HCP-administered only. No new boxed warning. Approval supported by Phase 3 INSPIRE-1 and INSPIRE-2 trials.
Priority Review
Next-generation oral TYK2 inhibitor. FDA accepted the NDA under Priority Review on September 14, 2026, with a target action date in Q1 2027. The EMA accepted the marketing authorisation application in parallel. Phase 3 LATITUDE-PsO-3001/3002 positive; Phase 3 for psoriatic arthritis ongoing. Still investigational, not approved anywhere.
Phase 3 complete
Next-generation oral TYK2 inhibitor. Phase 3 ONWARD1 and ONWARD2 met all primary and secondary endpoints, PASI 75 around 74%, with 54% achieving clear skin at 48 weeks in the ONWARD3 extension. NDA submission to the FDA planned for Q4 2026; not yet filed.
Atopic Dermatitis
FDA Approved
IL-13 inhibitor. FDA approved June 9, 2026 a new every-8-week (Q8W) maintenance dosing regimen for atopic dermatitis. After induction (500mg at wks 0 and 2, then 250mg Q2W through wk16), patients may now maintain on 250mg Q8W OR Q4W — as few as 6 injections per year. Only biologic for AD with an approved Q8W maintenance regimen. Supported by ADjoin Phase 3 LTE and exposure-response modeling.
Discontinued
Anti-OX40L biologic. Sanofi announced on July 24, 2026 that it will not submit amlitelimab for atopic dermatitis to any regulator, ending the programme in this indication despite positive Phase 3 COAST 1/2 and SHORE results. Development continues in other indications.
Phase 3
Oral TYK2 inhibitor for AD. Phase 2 positive (JAMA Derm 2026). Phase 3 (579 patients) underway.
Discontinued
Anti-OX40 biologic. Phase 3 met endpoints but discontinued March 2026 due to emerging safety concerns.
Hidradenitis Suppurativa
Phase 3 complete
Oral JAK1 inhibitor. Phase 3 STOP-HS1/2 positive, HiSCR50 around 60 to 71%, with 54-week data presented at AAD 2026. US regulatory filing has been signalled but no FDA acceptance or action date has been announced. Also in Phase 3 for vitiligo and prurigo nodularis.
BLA Submitted
IL-17A/F nanobody. Phase 3 (VELA-1/2) — VELA-1 met endpoint; VELA-2 narrowly missed. BLA submitted to the FDA. BLA includes adults and adolescents ≥12y. Priority Review designation to be requested. Positive final pre-BLA meeting with FDA confirmed. 52-week VELA extension data: HiSCR75 67.2%. FDA acceptance and Priority Review decision expected within 60 days of filing; potential US launch H2 2027 under standard review.
Alopecia Areata
FDA Approved
JAK1/2 inhibitor. FDA approved September 25, 2026 (sNDA) for severe alopecia areata in adolescents ≥12y weighing ≥30 kg — expanding the prior adult-only (≥18y) indication. Dosing: 2 mg once daily; may escalate to 4 mg for inadequate response or near-complete/complete scalp hair loss; may reduce back to 2 mg once adequate response achieved. BBW carried into pediatric label unchanged (serious infections, malignancy, MACE, thrombosis). Pre-initiation: TB screening; monitoring: CBC and lipids at ~12 weeks; avoid live vaccines. Based on BRAVE-AA-PEDS Phase 3 trial (NCT05723198). Second JAK inhibitor cleared for adolescents with severe AA after ritlecitinib (Litfulo).
sNDA Under FDA Review
Oral JAK1 inhibitor. AbbVie submitted an sNDA to the FDA on April 28, 2026 for severe alopecia areata in adults and adolescents, and the EU CHMP issued a positive opinion on June 29, 2026. Phase 3 showed full scalp regrowth in a majority of treated patients. Not yet FDA approved for alopecia areata, so it is not listed among the approved agents for that diagnosis. Carries the systemic JAK class black box warning.
Vitiligo
sNDA/sMAA Under FDA & EMA Review
Full Phase 3 Viti-Up-1 & Viti-Up-2 results published The Lancet (August 15, 2026). Co-primary endpoints T-VASI50 and F-VASI75 both met at Week 48. sNDA/sMAA submitted to FDA & EMA on February 3, 2026. The European Commission approved it for adults and adolescents with non-segmental vitiligo on July 29, 2026; the FDA review is still ongoing with no confirmed action date. Would be the first systemic therapy approved for vitiligo in the US.
Phase 3
JAK3/TEC inhibitor. Phase 3 for vitiligo ongoing (est. completion 2026). Already approved for alopecia areata (Litfulo).
Pemphigus Vulgaris & Other
FDA Approved
Anti-CD20 monoclonal antibody biosimilar referencing Rituxan (rituximab). FDA approved 2026-08-01 for moderate-to-severe pemphigus vulgaris in adults (≥18y). US commercial launch date not yet announced as of 2026-08-23. Not designated interchangeable at time of approval. BBW: fatal infusion-related reactions, severe mucocutaneous reactions, hepatitis B virus reactivation, progressive multifocal leukoencephalopathy (PML). Note: Truxima (rituximab-abbs) received interchangeability designation 2026-07-01 — flagged for separate review.
FDA Approved
Oral TYK2/JAK1 inhibitor. FDA approved August 27, 2026 as the first oral treatment for dermatomyositis in adults (≥18y). 30 mg once daily. Based on Phase 3 VALOR trial (N=241). BBW: serious infections, malignancy, MACE, thrombosis. Not recommended in combination with other JAK inhibitors, TYK2 inhibitors, or biologic DMARDs.
ⓘ  Each drug name links to its source: the FDA label or approval announcement for approved agents, and the company announcement, published results or trial record for the rest. Trials listed reflect late-stage (Phase 2b–3) programs with data presented at AAD 2026, EADV 2025, or published as of April 2026. Phase status reflects most recent available data. NDA/BLA = New Drug Application / Biologics License Application filing with FDA. This section is updated periodically — visit ClinicalTrials.gov for real-time status.
Evidence base & sources
AAD Clinical Guidelines
American Academy of Dermatology practice guidelines for psoriasis, atopic dermatitis, hidradenitis suppurativa, and alopecia areata — the primary evidence-based standard for US dermatology practice.
FDA Prescribing Information
Official FDA-approved labels for every biologic, JAK inhibitor, and TYK2 inhibitor in the tool — authoritative source for approved indications, dosing schedules, contraindications, and black box warnings.
Landmark Clinical Trials
Phase 3 registration trials published in NEJM, Lancet, and JAAD including SOLO 1&2, ERASURE/FIXTURE, BE SURE, VOYAGE, UltIMMa, BRAVE-AA, TRuE-V, PIONEER, LIBERTY-BP, and others.
DermSquared Biologics Tool v9
Brownstone & Lebwohl (October 2025) — quick reference chart for approved biologic dosing across psoriasis, HS, AD, PN, CSU, and BP. Used as a cross-reference for dosing accuracy.
AAAAI / EAACI Guidelines
International urticaria guidelines used for chronic spontaneous urticaria biologic selection, including omalizumab and dupilumab positioning.
UpToDate
Evidence-based clinical decision support used to cross-reference treatment algorithms for psoriasis, atopic dermatitis, and other conditions covered in this tool.
Content is reviewed against current literature and updated periodically. DermRx is intended for clinical decision support and educational purposes only — not a substitute for clinical judgment or institutional prescribing guidelines. Clinicians should consult primary sources and current package inserts before prescribing.
Created by Aleena Boby, MD candidate — University of South Florida · aleenaboby.com